Your Prostrate.com logo
Google
Web yourprostate.com.au

Prostate News Archive

04-Dec-2008

  • Cell Genesys and Takeda Announce Termination of Collaboration Agreement for GVAX Immunotherapy for Prostate Cancer (Centre Daily Times)

    Cell Genesys, Inc. (Nasdaq:CEGE) and Takeda Pharmaceutical Company Limited (TSE:4502), together with its wholly owned subsidiary Millennium: The Takeda Oncology Company, today announced that they have mutually agreed to suspend the further development of GVAX immunotherapy for prostate cancer and that Takeda has ended the collaboration agreement with Cell Genesys for the development and ...


  • Degarelix prostate cancer drug makes testosterone levels fall dramatically and quickly (News-Medical-Net)

    More than 95 per cent of men who took degarelix for prostate cancer saw their testosterone levels fall dramatically as early as three days after they started treatment, according to a paper in the December issue of BJU International.


  • HHS grant will fund prostate research (The Iowa City Press-Citizen)

    The University of Iowa has received a $148,941 grant from the U.S. Department of Health and Human Services to fund prostate cancer research, Rep. Dave Loebsack, D-Iowa, announced.


  • OGX-011 Shows Overall Survival Advantage In Prostate Cancer Compared To Standard Therapy In A Randomized Phase 2 Study (Medical News Today)

    OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced positive survival results from a randomized Phase 2 clinical trial of OGX-011 in combination with docetaxel and prednisone ("the OGX-011 arm") compared to docetaxel and prednisone alone ("the control arm") for first-line treatment of metastatic castrate resistant prostate cancer. The current 10.


  • Phase II Study Shows That ZD4054 Could Improve Survival For Hormone Resistant Prostate Cancer (HRPC) Patients With ... (Medical News Today)

    A novel compound in development by AstraZeneca as an oral tablet for hormone resistant prostate cancer (HRPC), ZD4054, could improve overall survival (OS) in men with metastatic HRPC, according to Phase II data published today in European Urology.


  • Back to Prostate News Archive